phenylephrine-hydrochloride and Scleroderma--Systemic

phenylephrine-hydrochloride has been researched along with Scleroderma--Systemic* in 1 studies

Other Studies

1 other study(ies) available for phenylephrine-hydrochloride and Scleroderma--Systemic

ArticleYear
The effect of nasal CPAP on nocturnal reflux in patients with aperistaltic esophagus.
    Chest, 1994, Volume: 106, Issue:3

    It has been shown that nasal continuous positive airway pressure (nasal CPAP) significantly reduces nocturnal reflux both in patients with sleep apnea and in patients without sleep apnea but consistent abnormal nocturnal reflux. The mechanism by which CPAP is thought to reduce reflux includes the elevation of the resting lower esophageal sphincter (LES) pressure. In this study, we tested the effect of nasal CPAP in two groups of patients with aperistaltic esophagus but with different resting LES pressure. Seven patients with scleroderma esophagus and six patients treated for achalasia were tested over a 48-h period. On the first night, the patients were untreated; on the second night, both groups received applied nasal CPAP at 8 cm H2O pressure. The percentage of time the pH < 4.0, the number of reflux events > 5 min, and the length of the longest reflux event were all significantly reduced in the patients with achalasia (p < 0.03), but not in the scleroderma group (p > 0.20). These results suggest that a residual resting LES pressure greater than that demonstrated by patients with scleroderma (> 10 mm Hg) may be necessary for nasal CPAP to affect nocturnal reflux.

    Topics: Adult; Aged; Aged, 80 and over; Esophageal Achalasia; Esophagus; Evaluation Studies as Topic; Female; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Middle Aged; Nose; Peristalsis; Polysomnography; Positive-Pressure Respiration; Raynaud Disease; Scleroderma, Systemic

1994